Liminatus Pharma Raises $4M in 13.8M Share Offering with Warrants
Liminatus Pharma priced a best-efforts public offering of 13,813,000 common shares and warrants for 20,719,500 shares at $0.29 each, raising gross proceeds of $4.0 million. Full warrant exercise could provide an additional $6.0 million; net proceeds will fund working capital and corporate objectives.
1. Pricing and Terms of Offering
Liminatus Pharma has priced a best-efforts offering of 13,813,000 common shares and warrants to purchase 20,719,500 shares at a combined price of $0.29 per share. The warrants carry a $0.29 exercise price, are exercisable immediately, and will expire five years from issuance.
2. Potential Additional Proceeds
If all warrants are exercised on a cash basis, the company expects to receive approximately $6.0 million in additional gross proceeds, potentially boosting total capital raised to $10.0 million before fees and expenses.
3. Use of Proceeds
Net proceeds are earmarked for working capital, general corporate purposes, and the advancement of Liminatus’s next-generation CD47-blockade immuno-oncology programs.
4. Closing and Placement Agent
The offering is expected to close on or about February 18, 2026, subject to customary closing conditions, with Maxim Group LLC acting as sole placement agent under an effective Form S-1 registration.